The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000277.2(PAH):c.1200-8G>A

CA229395

102565 (ClinVar)

Gene: PAH
Condition: phenylketonuria
Inheritance Mode: Autosomal recessive inheritance
UUID: efeae3bc-42d1-44aa-9a8b-de32b8bad069
Approved on: 2019-09-29
Published on: 2019-09-29

HGVS expressions

NM_000277.2:c.1200-8G>A
NM_000277.2(PAH):c.1200-8G>A
NC_000012.12:g.102840523C>T
CM000674.2:g.102840523C>T
NC_000012.11:g.103234301C>T
CM000674.1:g.103234301C>T
NC_000012.10:g.101758431C>T
NG_008690.1:g.82080G>A
NG_008690.2:g.122888G>A
NM_000277.1:c.1200-8G>A
NM_001354304.1:c.1200-8G>A
NM_000277.3:c.1200-8G>A
ENST00000307000.7:c.1185-8G>A
ENST00000549247.6:n.959-8G>A
ENST00000551114.2:n.862-8G>A
ENST00000553106.5:c.1200-8G>A
ENST00000635477.1:n.304-8G>A
ENST00000635528.1:n.715-8G>A

Likely Pathogenic

Met criteria codes 4
PM2 PM3 PP4_Moderate PP3

Evidence Links 3

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Phenylketonuria VCEP
The c.1200-8G>A variant in PAH has been reported in multiple patients with PAH deficiency. BH4 deficiency excluded (PMID: 9391881, 23062575). This variant has extremely low frequency in gnomAD (MAF=0.00001) (PM2). This variant was detected with known pathogenic variants IVS10-11G>A, p.A403V (PM3). Computational evidence supports a splicing effect (HSF and MaxEnt). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3.
Met criteria codes
PM2
Extremely low frequency in gnomAD (MAF=0.00001)
PM3
Detected with known pathogenic variants IVS10-11G>A, p.A403V. Parental confirmation not reported.

PP4_Moderate
Detected in multiple patients with PAH deficiency. BH4 deficiency excluded (PMID: 9391881, 23062575)

PP3
HSF: Activation of an intronic cryptic acceptor site (+61.02%). Potential alteration of splicing. MaxEnt: Alteration of the WT acceptor site, most probably affecting splicing (-70.4%).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.